Beatriz Helena Carlini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Beatriz Helena Carlini has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Sharon B. Garrett
Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
8 shared publications Sharon B. Garrett
Department of Psychiatry and Behavioral Sciences, Addictions, Drug & Alcohol Institute, University of Washington, Seattle, Washington
3 shared publicationsTerry Bush
Optum, Seattle, WA, USA
3 shared publications- Babalola Faseru
Department of Population Health, University of Kansas School of Medicine, Kansas City, KS, USA
2 shared publications Brooke Magnusson
Optum, Seattle, WA, USA
2 shared publications- Edward F. Ellerbeck
Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
2 shared publications
Latest Publications
- 30 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 852-863
Cannabis-Related Problems, Adverse Events, Clinical Experiences and Barriers to Intervening: Perspectives of Health Care Providers in Washington State
Background: Patients presenting with cannabis-related adverse events (AEs) and other problems are becoming increasingly prevalent in health care settings across the U.S. and Canada, increasing the burden on providers and health systems. Understanding how healthcare providers perceive and respond to cannabis AEs can inform medical training and clinical practices, health policy, and systems-level interventions. Methods: The study was conducted in Washington State, a U.S. state that legalized cannabis for non-medical use in 2012. Health care providers were invited to complete an anonymous online survey between December 2024 and March 2025, eliciting frequency and seriousness of various cannabis-related AEs, related clinical practices and procedures, knowledge and confidence addressing such problems, level of concern, and barriers and facilitators to identifying and intervening in such events. Results: Three hundred and eighty-eight valid survey responses were included in the analysis. Most respondents were mdical doctors and worked in hospitals or primary care clinics. Thirty-five percent of respondents reported seeing cannabis AEs and use-related problems frequently (at least 2-3 times a month) in clinical practice. Severe cyclic vomiting was most common (70% reported it ever occurred) and was second to psychosis as “most serious” (33% and 34%). While most providers saw screening and intervening as important (90%), only 39.1% reported universally screening for cannabis and identified many barriers to intervening. Conclusion: Health care providers in a legal cannabis state have encountered AEs and other complications related to cannabis use, and many are concerned about their frequency and severity. According to study participants, expanding access to clinical guidelines, validated tools, referral pathways, and specialized training may enhance their willingness and capacity to screen and intervene effectively.
- 30 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 852-863
Cannabis-Related Problems, Adverse Events, Clinical Experiences and Barriers to Intervening: Perspectives of Health Care Providers in Washington State
Background: Patients presenting with cannabis-related adverse events (AEs) and other problems are becoming increasingly prevalent in health care settings across the U.S. and Canada, increasing the burden on providers and health systems. Understanding how healthcare providers perceive and respond to cannabis AEs can inform medical training and clinical practices, health policy, and systems-level interventions. Methods: The study was conducted in Washington State, a U.S. state that legalized cannabis for non-medical use in 2012. Health care providers were invited to complete an anonymous online survey between December 2024 and March 2025, eliciting frequency and seriousness of various cannabis-related AEs, related clinical practices and procedures, knowledge and confidence addressing such problems, level of concern, and barriers and facilitators to identifying and intervening in such events. Results: Three hundred and eighty-eight valid survey responses were included in the analysis. Most respondents were mdical doctors and worked in hospitals or primary care clinics. Thirty-five percent of respondents reported seeing cannabis AEs and use-related problems frequently (at least 2-3 times a month) in clinical practice. Severe cyclic vomiting was most common (70% reported it ever occurred) and was second to psychosis as “most serious” (33% and 34%). While most providers saw screening and intervening as important (90%), only 39.1% reported universally screening for cannabis and identified many barriers to intervening. Conclusion: Health care providers in a legal cannabis state have encountered AEs and other complications related to cannabis use, and many are concerned about their frequency and severity. According to study participants, expanding access to clinical guidelines, validated tools, referral pathways, and specialized training may enhance their willingness and capacity to screen and intervene effectively.
- 16 January 2026
- Published by Springer Nature in Community Mental Health Journal
- Vol. 62 (5) , 889-895
People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: a study in WA State, USA
Cannabis use has been shown to negatively impact the management and prognosis of psychotic disorders. Little is known about the broader health impacts of cannabis use in this population. This study compares cannabis-related negative health outcomes among individuals with a diagnosis of a psychotic disorder to those with other mental health (MH) diagnoses or no MH diagnosis. Data came from International Cannabis Policy Study (2020–2023). Respondents were 4,144 Washington State individuals aged 16–65, who consumed cannabis in the last 12 months. Three groups were compared for cannabis use negative health events: lifetime diagnoses of psychotic disorders, other MH and no MH diagnoses. Logistic regressions were used in the analysis. People with psychotic disorders were more likely to report adverse events from their cannabis use and to pursue medical attention than consumers with other MH or no MH diagnoses (p < .001.) They had higher likelihood of nausea/vomiting, heart or blood pressure problems, fainting, acute psychosis or hallucinations, flashbacks, Cannabis Hyperemesis Syndrome, and positive screening for high-risk cannabis use than consumers with other MH or no MH diagnoses. Individuals with psychotic disorder experience more adverse health events from cannabis, including events not associated with exacerbation of their disorders. These findings highlight the need to develop focused clinical interventions and awareness campaigns to address elevated risks of cannabis use among this vulnerable population.
- 16 January 2026
- Published by Springer Nature in Community Mental Health Journal
- Vol. 62 (5) , 889-895
People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: a study in WA State, USA
Cannabis use has been shown to negatively impact the management and prognosis of psychotic disorders. Little is known about the broader health impacts of cannabis use in this population. This study compares cannabis-related negative health outcomes among individuals with a diagnosis of a psychotic disorder to those with other mental health (MH) diagnoses or no MH diagnosis. Data came from International Cannabis Policy Study (2020–2023). Respondents were 4,144 Washington State individuals aged 16–65, who consumed cannabis in the last 12 months. Three groups were compared for cannabis use negative health events: lifetime diagnoses of psychotic disorders, other MH and no MH diagnoses. Logistic regressions were used in the analysis. People with psychotic disorders were more likely to report adverse events from their cannabis use and to pursue medical attention than consumers with other MH or no MH diagnoses (p < .001.) They had higher likelihood of nausea/vomiting, heart or blood pressure problems, fainting, acute psychosis or hallucinations, flashbacks, Cannabis Hyperemesis Syndrome, and positive screening for high-risk cannabis use than consumers with other MH or no MH diagnoses. Individuals with psychotic disorder experience more adverse health events from cannabis, including events not associated with exacerbation of their disorders. These findings highlight the need to develop focused clinical interventions and awareness campaigns to address elevated risks of cannabis use among this vulnerable population.
- Open Access
- 21 May 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 273, 112728
Cannabis consumption patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State
- 21 May 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 273, 112728
Open AccessCannabis consumption patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State
- 20 April 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102102
Trends in varenicline use for tobacco cessation, and their implications
- 20 April 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102102
Trends in varenicline use for tobacco cessation, and their implications
- 2 December 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 123, 104270
Identifying policy options to regulate high potency cannabis: A multiple stakeholder concept mapping study in Washington State, USA
- 2 December 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 123, 104270
Identifying policy options to regulate high potency cannabis: A multiple stakeholder concept mapping study in Washington State, USA
- 1 September 2022
- Published by Alcohol Research Documentation, Inc. in Journal of Studies on Alcohol and Drugs
- Vol. 83 (5) , 771-772
The Kids Are Not All Right: E-Cigarettes, Cannabis Co-Use, and an Emerging Public Health Crisis—A Commentary on Roberts et al. (2022)
- 1 September 2022
- Published by Alcohol Research Documentation, Inc. in Journal of Studies on Alcohol and Drugs
- Vol. 83 (5) , 771-772
The Kids Are Not All Right: E-Cigarettes, Cannabis Co-Use, and an Emerging Public Health Crisis—A Commentary on Roberts et al. (2022)
- Open Access
- 22 July 2022
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 4 (1) , 1-8
Cannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators
Background: The prevalence of adults who consume cannabis while abstaining from other substances is not known in the USA. This study used nationally representative data to estimate the prevalence and explore the demographic characteristics, cannabis use behaviors, and self-reported health of US adults with past 30-day cannabis-only use, as compared with adults who used cannabis as well as other substances. Methods: Data came from adults 18 years and older who responded to the 2017 or 2018 National Survey on Drug Use and Health and reported past 30-day cannabis use (n = 12,143). Cannabis-only use was defined as past 30-day cannabis use with no past 30-day use of other substances (alcohol, tobacco, other illicit substances, non-prescribed controlled medications). Weighted frequencies and 95% confidence intervals (CI) were computed for all sociodemographic and cannabis-related variables, overall, and across the two categories of cannabis consumers, stratified by age. Results: The prevalence of past 30-day cannabis-only use among US adults was 0.9% (95% CI: 0.8, 1.0) and varied by age (2.0% of 18–25 years old; 0.7% of 26–49 year olds, and 0.6% of those ≥ 50 years). Among adults with any past 30-day cannabis use, 8.4% (95% CI: 7.6, 9.2; n = 980) reported cannabis-only use. Age was significantly associated with past 30-day cannabis-only use, with adults 18–25 years and 26–49 years having higher odds of cannabis-only use compared with older adults. Past year cannabis dependence was lowest among cannabis-only consumers aged ≥ 50 years (0.2%; 95% CI: 0.1, 0.5) and highest among young adult cannabis and other substance consumers (16.7%; 95% CI: 15.3, 18.2). Past year prevalence of any mental illness was generally similar across cannabis use groups and by age. Conclusions: The prevalence of adult cannabis-only use in the US is low — most cannabis consumers report using other substances in the past 30 days as well. While cannabis-only use among older adults is rare, it does not appear to be accompanied by a high prevalence of dependence. These findings should guide future research and policymaking.
- 22 July 2022
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 4 (1) , 1-8
Open AccessCannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators
Background: The prevalence of adults who consume cannabis while abstaining from other substances is not known in the USA. This study used nationally representative data to estimate the prevalence and explore the demographic characteristics, cannabis use behaviors, and self-reported health of US adults with past 30-day cannabis-only use, as compared with adults who used cannabis as well as other substances. Methods: Data came from adults 18 years and older who responded to the 2017 or 2018 National Survey on Drug Use and Health and reported past 30-day cannabis use (n = 12,143). Cannabis-only use was defined as past 30-day cannabis use with no past 30-day use of other substances (alcohol, tobacco, other illicit substances, non-prescribed controlled medications). Weighted frequencies and 95% confidence intervals (CI) were computed for all sociodemographic and cannabis-related variables, overall, and across the two categories of cannabis consumers, stratified by age. Results: The prevalence of past 30-day cannabis-only use among US adults was 0.9% (95% CI: 0.8, 1.0) and varied by age (2.0% of 18–25 years old; 0.7% of 26–49 year olds, and 0.6% of those ≥ 50 years). Among adults with any past 30-day cannabis use, 8.4% (95% CI: 7.6, 9.2; n = 980) reported cannabis-only use. Age was significantly associated with past 30-day cannabis-only use, with adults 18–25 years and 26–49 years having higher odds of cannabis-only use compared with older adults. Past year cannabis dependence was lowest among cannabis-only consumers aged ≥ 50 years (0.2%; 95% CI: 0.1, 0.5) and highest among young adult cannabis and other substance consumers (16.7%; 95% CI: 15.3, 18.2). Past year prevalence of any mental illness was generally similar across cannabis use groups and by age. Conclusions: The prevalence of adult cannabis-only use in the US is low — most cannabis consumers report using other substances in the past 30 days as well. While cannabis-only use among older adults is rare, it does not appear to be accompanied by a high prevalence of dependence. These findings should guide future research and policymaking.
- 25 March 2022
- Published by Elsevier in Health & Place
- Vol. 75, 102795
Retail cannabis environment and adolescent use: The role of advertising and retailers near home and school
- 25 March 2022
- Published by Elsevier in Health & Place
- Vol. 75, 102795
Retail cannabis environment and adolescent use: The role of advertising and retailers near home and school
- 29 March 2021
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (1) , 34-42
Cannabis Retail Staff (“Budtenders”) Attitudes Towards Cannabis Effects on Health and Experiences Interacting with Consumers – Washington State, USA
Cannabis legalization in Washington State has increased the availability, consumption, and potency of cannabis products for adults. Public health education promoting safe use for adult consumers has lagged behind these trends. This study assesses the potential of cannabis retail workers (budtenders) to engage in responsible use education with adult consumers at point of sale. Focus groups explored how budtenders perceive their professional role, including educating consumers about cannabis over intoxication, storage, and risks of use before driving and during pregnancy. Transcripts were analyzed to develop a coding scheme, which was then applied with an iterative review by the research team. Budtenders identified three main professional roles: creating a good experience for customers; being compliant with the state law and regulations, and educating customers on products. Budtenders did not believe their job involved discussing use during pregnancy or while driving or safe storage. They prioritized customers’ autonomy over education on these topics, and they did not necessarily consider these behaviors to be harmful. Budtenders are committed to keeping minors outside stores and educating consumers on how to avoid over intoxication and exposure to cannabis contaminants. Future research could build on this to develop point-of-sale education to reduce cannabis use risks.
- 29 March 2021
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (1) , 34-42
Cannabis Retail Staff (“Budtenders”) Attitudes Towards Cannabis Effects on Health and Experiences Interacting with Consumers – Washington State, USA
Cannabis legalization in Washington State has increased the availability, consumption, and potency of cannabis products for adults. Public health education promoting safe use for adult consumers has lagged behind these trends. This study assesses the potential of cannabis retail workers (budtenders) to engage in responsible use education with adult consumers at point of sale. Focus groups explored how budtenders perceive their professional role, including educating consumers about cannabis over intoxication, storage, and risks of use before driving and during pregnancy. Transcripts were analyzed to develop a coding scheme, which was then applied with an iterative review by the research team. Budtenders identified three main professional roles: creating a good experience for customers; being compliant with the state law and regulations, and educating customers on products. Budtenders did not believe their job involved discussing use during pregnancy or while driving or safe storage. They prioritized customers’ autonomy over education on these topics, and they did not necessarily consider these behaviors to be harmful. Budtenders are committed to keeping minors outside stores and educating consumers on how to avoid over intoxication and exposure to cannabis contaminants. Future research could build on this to develop point-of-sale education to reduce cannabis use risks.
- 1 December 2020
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 34 (8) , 894-897
Understanding the intergenerational transmission of substance use and problem behavior: Implications for future research and preventive interventions.
The Constitution of the Iroquois Nation states that we should "look and listen for the welfare of the whole people and have always in view not only the present, but also the coming generations." The excellent intergenerational longitudinal studies represented here help us better understand patterns of behaviors across generations. Collectively, these studies provide a pathway for future research on contexts and trends in substance use, research on age of onset among early generations, and research related to epigenetics to improve prevention interventions. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- 1 December 2020
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 34 (8) , 894-897
Understanding the intergenerational transmission of substance use and problem behavior: Implications for future research and preventive interventions.
The Constitution of the Iroquois Nation states that we should "look and listen for the welfare of the whole people and have always in view not only the present, but also the coming generations." The excellent intergenerational longitudinal studies represented here help us better understand patterns of behaviors across generations. Collectively, these studies provide a pathway for future research on contexts and trends in substance use, research on age of onset among early generations, and research related to epigenetics to improve prevention interventions. (PsycInfo Database Record (c) 2020 APA, all rights reserved).